Epicardial adipose tissue (EAT) is the visceral fat of the heart, sharing many of the pathophysiological properties of other visceral fat depots. EAT is a metabolically active paracrine and vasocrine organ that causes local cardiac inflammation and is strongly implicated in the pathogenesis of coronary atherosclerosis. This article highlights the findings of recent observational studies in patients on haemodialysis that link the quantity of EAT to increased rates of cardiovascular and coronary artery disease and review the proposed methods of pathogenesis and the possible role of EAT quantification to improve cardiovascular risk assessment.
INTRODUCTION
Epicardial adipose tissue (EAT) is a metabolically active visceral fat deposit that covers 80% of the cardiac surface and accounts for approximately 20% of total cardiac weight. Similar to other white adipose tissues, EAT has endocrine functions with the ability to secrete hormones and inflammatory cytokines. The physiological function of EAT remains unclear, but is thought to include regulation of local fatty acid homeostasis, provision of an immediate local energy source, assisting in coronary artery remodelling and supporting coronary arteries against torsion from cardiac contraction and arterial pulse wave [1, 2] . The expression and secretion of proinflammatory cytokines, such as interleukin-6, interleukin-1b, monocyte chemoattractant protein 1 and tumour necrosis factor-a, are higher in the EAT of patients with coronary heart disease than in subcutaneous fat of the same individuals, and the pathological enlargement of EAT correlates significantly with increased cardiovascular disease (CVD) risk [3, 4] . The importance of EAT in relation to the inflammatory burden in CVD is established [5, 6] with paracrine and vasocrine secretion of proinflammatory adipokines. Adipokines are thought to directly contribute to myocardial inflammation, left ventricular hypertrophy (LVH), coronary artery disease (CAD) and myocardial dysfunction through generation of local reactive oxygen species, creating a proatherogenic state and as a direct local effect of inflammatory cytokines [4, 7] . Although obesity and BMI are commonly used and easily obtainable figures to stratify patients' cardiometabolic and atherosclerotic risk, they are far from perfect. There is good evidence from prospective, cross-sectional imaging and anthropometric studies that regional distribution of adipose tissue rather than an overall excess of body fat correlates with CVD and its associated risk [8] [9] [10] . Furthermore, the association between EAT and CAD has been shown to be independent of BMI and diabetic status [3] .
EAT and its relevance in the pathogenesis of CVD among patients with end-stage renal disease (ESRD) on haemodialysis is a relatively underresearched area. Chronic kidney disease (CKD) is a chronic inflammatory condition, as evidenced by increased circulating levels of acute-phase proteins and proinflammatory cytokines, such as C-reactive protein, interleukin-6 and tumour necrosis factor-a [11] . Both inflammation and oxidative stress play central roles in the development of atherosclerosis in patients with CKD, and in functional CVDrelated outcomes, including pathogenesis of LVH, arterial stiffness and global cardiac function [12, 13] . Recently, the associations between increased EAT thickness, interleukin-6 and coronary artery calcification (CAC) in patients with CKD stages 3-5 [14] have been demonstrated. In addition, increasing volumes of EAT in this patient population are associated with an increasing risk of cardiovascular events, independent of general adiposity, and are a better predictor of risk than abdominal visceral adipose tissue [15 & ]. This review summarizes the role EAT may play in pathogenesis of CVD in patients on haemodialysis and whether imaging EAT may hold prognostic implications for cardiovascular events and mortality within this patient group.
EPICARDIAL ADIPOSE TISSUE MEASUREMENT
EAT can be measured in a number of ways using different imaging modalities. The three commonly used methods are transthoracic echocardiography (ECHO), computerized axial tomography scanning (CT scanning) and cardiac MRI (CMR). The relative strengths and weaknesses of these modalities are summarized in Table 1 . CMR and CT are threedimensional imaging techniques which allow calculation of total EAT volume whereas ECHO is primarily a two-dimensional technique. Although ECHO is widely available and relatively inexpensive, views of the heart may be limited by obesity, small rib spaces and lung disease. The ability to differentiate adipose tissue from other tissues is also limited and operator dependent.
KEY POINTS
EAT is likely to play a key role in the pathogenesis of CVD and CAD in patients on haemodialysis through direct paracrine and vasocrine secretion of proinflammatory and proatherogenic cytokines into the myocardium.
EAT measurement is likely to have a role in cardiovascular and cardiometabolic risk stratification for patients on haemodialysis.
EAT has been shown to be modifiable and as it potentially drives LVH, myocardial inflammation, endothelial dysfunction and coronary artery calcification; it is an attractive therapeutic target. ECHO imaging studies have shown that the mean EAT thickness at the right ventricular wall correlates significantly (r ¼ 0.840, P ¼ 0.01) with volume measurements using CMR [16] . Unfortunately, EAT thickness is only a surrogate marker for EAT volume, making it a suboptimal imaging modality for prospective studies and clinical trials where absolute quantification of EAT volume is required. In addition, the low spatial resolution and operator dependency of ECHO makes delineating EAT from pericardial fat (or fluid) difficult, resulting in lower reproducibility compared with CT and MRI [17] . Unlike ECHO, cardiac CT can give excellent, reproducible three-dimensional images and volume measurements that can be obtained without the use of intravenous contrast. However, cardiac CT is costly and exposes patients to ionizing radiation, although with the new faster scanners, the dose is considerably reduced. MRI is the gold standard for the assessment of total body fat and the reference modality for analysis of ventricular mass and volume [17] , making it the natural choice for measuring EAT. CMR is expensive and even more limited in its availability, but does not expose the patient to radiation or intravenous contrast media. Even in general populations, CMR and EAT studies have been done in only small samples of patients. How representative these patients are of the general population is questionable and consequently defining reference values has proved problematic. A recent systematic review, however, concluded that EAT volumes of more than 125 ml or 68 ml/m 2 , or EAT thickness more than 5 mm are abnormal [17] .
EPICARDIAL ADIPOSE TISSUE MEASUREMENT IN PATIENTS ON HAEMODIALYSIS
Several observational studies have looked at the thickness or volumes of EAT in patients on haemodialysis compared with matched control groups. These are summarized in Table 2 . Altun et al. [18 && ] were the first to demonstrate in an ECHO study of 62 patients on haemodialysis and 40 healthy controls that EAT thickness was significantly larger in patients on haemodialysis compared with controls (matched for age, sex, smoking status, BMI, cholesterol and triglyceride levels) and correlated positively with haemodialysis vintage. A further ECHO study by Atakan et al. [19 && ] of 71 patients on haemodialysis and 65 controls corroborated these findings, with controls in this study additionally matched for glucose levels. The first multidirectional computerized tomography (MDCT) study of EAT in patients on haemodialysis was undertaken by Tonbul et al. [20] who demonstrated that EAT volume was significantly larger in diabetic patients on haemodialysis than in both healthy controls and patients on haemodialysis without diabetes, suggesting that diabetic status may be the overriding driver behind EAT enlargement. However, a subsequent study using unenhanced coronary CT by Turkmen et al. [21] found that EAT volumes were significantly higher in patients with ESRD on dialysis compared with matched controls independent of diabetic status. In the same study, EAT volumes tended to be higher in patients on peritoneal dialysis compared with haemodialysis, but this did not reach statistical significance. A recent ECHO study by Colak et al. [22 && ] showed that EAT thickness was significantly greater in patients on haemodialysis compared with patients who had a renal transplant (matched for BMI, body surface area, glucose, cholesterol, triglycerides, age and sex) but who were of a similar dialysis vintage prior to transplantation. The EAT thickness in the renal transplant group in this study was also similar to age and sex-matched controls which may suggest there is something about the proinflammatory state of haemodialysis particularly that increases EAT thickness over and above the uraemic and inflammatory milieu associated with CKD alone.
All of these studies are observational and relatively small in size; nevertheless, the data available suggest that EAT volumes are larger in patients on haemodialysis compared with controls. There are currently no CMR studies that have assessed EAT in patients on haemodialysis.
EPICARDIAL ADIPOSE TISSUE AND CARDIOVASCULAR DISEASE RISK FACTORS IN PATIENTS ON HAEMODIALYSIS
Patients on haemodialysis display hugely elevated rates of cardiac mortality [24] , accounting for 43% of all-cause deaths in this group [25] . Although the prevalence of traditional risk factors of CVD is higher in haemodialysis patients, the increased rates of CVD are largely driven by nontraditional risk factors [26] . Several studies have reported significant associations between markers of CVD and EAT in patients on haemodialysis. These are summarized in Table 3 . A cross-sectional study by Erdur et al. [23] showed that EAT volume (measured by MDCT) and atherogenic index of plasma (AIP), a logarithmic ratio of triglycerides to high-density lipoprotein, were significantly higher in patients with ESRD on haemodialysis and peritoneal dialysis than in healthy controls. In addition, there were significant correlations between EAT, BMI and AIP, with no correlation between EAT and AIP in healthy controls. An interventional pilot study by by Wilund et al. [31] showed that intradialytic exercise significantly reduced not only EAT thickness but also serum lipid peroxidation (a marker of oxidative stress), suggesting a relationship between the two. This is the only interventional study looking at the effects of exercise on EAT in patients on haemodialysis. Gaus et al. [27] demonstrated in an observational study that EAT thickness measured using ECHO correlated well with BMI, smoking and age, and in a study of 191 prevalent patients on haemodialysis, Turan et al. [28] found that EAT volume (assessed by MDCT) correlated significantly with older age, female sex, BMI, higher total cholesterol and triglyceride content, and in adjusted models, older age, BMI and total cholesterol continued to associate with increased EAT volume. An echocardiographic study by Colak et al. [22 && ] demonstrated that inflammatory markers (including C-reactive protein and interleukin-6) and cardiac volume indices (including left atrium index, left atrium diameter and inferior vena cava-collapse index) were significantly raised in patients on haemodialysis and correlated significantly with EAT thickness when compared with both renal transplant and control patients. No such association was found between EAT thickness and these markers in the transplant patients [22 && ]. Turkmen et al. [21] found significant relationships between EAT volume (assessed with MDCT) and increasing components of the malnutrition, inflammation and atherosclerosis/calcification syndrome. The malnutrition, inflammation and atherosclerosis/calcification syndrome is defined as the interaction between proinflammatory cytokines, malnutrition and atherosclerosis in ESRD [31, 32] , which has been shown to be strongly associated with exceptionally high cardiovascular morbidity and mortality in patients with ESRD [33] . The same study by Turkmen et al. [21] also confirmed that increased volumes of EAT positively correlated with increasing age and BMI. It should be noted that the study population included patients with ESRD on haemodialysis and peritoneal dialysis.
EPICARDIAL ADIPOSE TISSUE AND CORONARY ARTERY DISEASE IN PATIENTS ON HAEMODIALYSIS
EAT has been strongly associated with both the existence and severity of CAD [34] [35] [36] ; even patients with asymptomatic CAD have been found to have increased EAT volumes [37] . A meta-analysis in 2012 of 2872 patients with CAD concluded that on the available evidence, EAT is an effective biomarker for the prediction of CAD [36] .
The body of evidence for patients on haemodialysis is somewhat smaller, but there are good observational data available. Atakan et al. [19 && ] found with an echocardiographic study that EAT thickness inversely correlated with coronary flow reserve (CFR) in patients on haemodialysis [19 && ]. CFR is a measure of how much coronary blood flow can increase and in the absence of epicardial disease reflects microvascular function. CFR has been used as a method for detecting endothelial dysfunction in nonrenal populations and subsequent subclinical atherosclerotic CAD [38] [39] [40] . Endothelial dysfunction has also been shown to be a nontraditional risk factor for CAD and CVD morbidity and mortality in patients with ESRD [41, 42] . Although the study by Atakan et al. [19 && ] is observational, it demonstrates a clear association between EAT and endothelial dysfunction and suggests the need for studies to look at causality. CAC is part of an extended state of vascular calcification that is detectable early in patients with ESRD and thought to contribute to both premature CVD and increased mortality [43] . The evidence for an association between EAT and CAC is conflicting.
In an observational study of 93 patients on haemodialysis, EAT assessed by echocardiography did not correlate with CAC except in younger patients [27] . However, an MDCT study of 60 patients on haemodialysis and 20 matched controls found CAC to be associated with EAT volume in both diabetic and nondiabetic patients with ESRD [20] . Similarly, Turkmen et al. [21] found that CACS and EAT volumes measured by CT were significantly higher in patients with ESRD on haemodialysis and peritoneal dialysis compared with healthy individuals and that there was a statistically significant relationship between EAT and CACS in all patients with ESRD.
Further prospective studies are required to assess this relationship. D'Marco et al. [29] demonstrated through post-hoc analysis of the Renagel in New Dialysis trial [44] that EAT volume was an independent predictor of mortality in incident patients on haemodialysis with a follow-up period of around 4 years. Multivariate analysis demonstrated that for each 10 cc increase in EAT volume, there was a 6% increase in risk of death during follow-up. This is the first study to describe a significant association between EAT and mortality in patients on haemodialysis, and corroborates the previously shown association of EAT with markers of vasculopathy such as CAC.
CLINICAL APPLICATIONS OF EPICARDIAL ADIPOSE TISSUE IN PATIENTS ON HAEMODIALYSIS
EAT measurement has the potential to add value to CVD risk stratification in patients with ESRD. In nonrenal groups, EAT has been shown to be a good predictor of CAD [36] . In patients with CKD not on ] demonstrated a robust association between EAT thickness, body fat accumulation, LVH, dyslipidaemia, insulin resistance and delivered dialysis dose. Further prospective studies are required to confirm whether there is any added value to current CVD screening tools from EAT measurement in patients on haemodialysis.
An interesting study by Karohl et al. [45] looked at the use of hybrid myocardial imaging for risk stratification prior to kidney transplantation. This was a retrospective study of 411 patients with CKD 4-5D, 284 of which were on haemodialysis. The study used PET-CT or single-photon emission CT to assess myocardial perfusion and quantify CAC and EAT. Myocardial perfusion defects were present in only 10% of all patients evaluated, and on multivariate logistic regression, EAT and CAC were independent predictors of abnormal myocardial perfusion, whereas presence of diabetes showed only a borderline association with the stress test result (P ¼ 0.08). EAT incrementally added to CAC for the prediction of an abnormal myocardial perfusion stress test, in a model including age, CAC and diabetes mellitus [area under the curve (AUC) 0.73 (95% confidence interval 0.64-0.81] to 0.76 (95% confidence interval 0.68-0.84, P ¼ 0.02] and was the best single predictor of abnormal myocardial perfusion. Although a retrospective study, this does suggest that EAT measurement may add some benefit to predicting myocardial perfusion defects in patients undergoing assessment for renal transplant. Further prospective studies are required and it should be noted that not all patients in this study had selective angiography, so confirmatory studies that include selective angiography are needed.
Two studies have shown that EAT is potentially modifiable in patients with haemodialysis. Wilund et al. [46] showed EAT thickness could be reduced with a programme of intradialytic exercise and Colak et al. [22 && ] showed that EAT thickness was significantly reduced in patients with renal transplant who had previously been on haemodialysis compared with well matched patients who were still on haemodialysis. Interventional studies that specifically target EAT reduction are needed, with mortality and cardiovascular events as endpoints. In addition, prospective studies that define the relationships between EAT and other risk factors, including silent and overt CAD, are required.
CONCLUSION
EAT is a metabolically active tissue which is increased in volume in patients on dialysis and likely has a role in the pathogenesis of CVD in patients on haemodialysis. We predict that EAT will have a role in the stratification of cardiovascular risk for patients on dialysis and those considered for renal transplantation. This is not only because it is a predictor of mortality in patients on haemodialysis but also because it improves sensitivity for predicting cardiovascular events. Finally, EAT is modifiable and may well be an attractive target for future interventional randomized controlled trials.
